Canfosfamide Hydrochloride(Canfosfamide Hydrochloride) - 药物靶点：DNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Canfosfamide、Canfosfamide hydrochloride (USAN)、TER 286

+ [4]

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)、DNA烷化剂

治疗领域

癌症内分泌与代谢疾病呼吸系统疾病+ [5]

在研适应症-

非在研适应症

晚期非小细胞肺癌恶性上皮肿瘤转移性乳腺癌+ [6]

原研机构

MabVax Therapeutics, Inc.

在研机构-

非在研机构

Taiho Pharmaceutical Co., Ltd.

Telik, Inc.

MabVax Therapeutics Holdings, Inc.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C26H41Cl5N5O10PS

InChIKeyNECZZOFFLFZNHL-XVGZVFJZSA-N

CAS号439943-59-6

关联

14

项与 Canfosfamide Hydrochloride 相关的临床试验

NCT01148108 / Completed临床2期

Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)

This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.

开始日期2010-06-01

申办/合作机构

Telik, Inc.

NCT00350948 / Terminated临床3期

Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)

The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.

开始日期2006-05-01

申办/合作机构

Telik, Inc.

NCT00102973 / Completed临床3期

Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]

The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.

开始日期2004-12-01

申办/合作机构

Telik, Inc.

100 项与 Canfosfamide Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Canfosfamide Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Canfosfamide Hydrochloride 相关的专利（医药）

登录后查看更多信息

28

项与 Canfosfamide Hydrochloride 相关的文献（医药）

2018-01-01·Neurourology and urodynamics

Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo‐controlled, double‐blind, parallel group study

Article

作者: Cardozo, Linda ; Bray, Rhiannon ; Hill, Simon ; Cartwright, Rufus ; Guan, Zhonghong ; Khullar, Vik

Aims:

We evaluated the effect of Tolterodine extended release (TER) versus placebo on bladder wall thickness (BWT) using transvaginal ultrasound in women with overactive bladder (OAB).

Materials and Methods:

We recruited 79 women with symptoms of OAB with a mean age of 47 years who had a BWT of at least 5 mm and a post‐micturition volume of less than 50 mL at screening. Subjects received TER 4 mg or placebo once daily for the first 12 weeks of the study. For the subsequent 12 weeks, all subjects received TER 4 mg once daily. BWT was measured at screening, weeks 12 and 24. Subjects recorded number of micturitions, incontinence episodes and urgency episodes, and volume voided per micturition at regular intervals during the study.

Results:

Treatment with TER for 12 weeks produced a statistically significant decrease from baseline in BWT (mean [SD] = 0.9 [1.4] mm; P < 0.05) that was not evident following treatment with placebo (0.2 [1.6] mm; P = 0.54). However, the treatment difference did not reach statistical significance (LS Mean = −0.4; 95%CI: −1.2, 0.3; P = 0.25). After 12 weeks of treatment, subjects who had taken TER showed an improvement in each bladder diary variable compared to placebo‐treated subjects.

Conclusions:

TER may have a direct effect on BWT in women with OAB. Larger studies are warranted to further investigate the effect of behavioral interventions and antimuscarinics, such as TER, on BWT in women with OAB and increased BWT.

2013-11-12·Biochemistry3区 · 生物学

Mechanism of Glutathione Transferase P1-1-Catalyzed Activation of the Prodrug Canfosfamide (TLK286, TELCYTA)

3区 · 生物学

Article

作者: Fernandes, Pedro Alexandrino ; Ramos, Maria João ; Mannervik, Bengt ; Dourado, Daniel F. A. R.

Canfosfamide (TLK286, TELCYTA) is a prodrug that upon activation by glutathione transferase P1-1 (GST P1-1) yields an anticancer alkylating agent and a glutathione derivative. The rationale underlying the use of TLK286 in chemotherapy is that tumor cells overexpressing GST P1-1 will be locally exposed to the released alkylating agent with limited collateral toxicity to the surrounding normal tissues. TLK286 has demonstrated clinical effects in phase II and III clinical trials for the treatment of malignancies, such as ovarian cancer, nonsmall cell lung cancer, and breast cancer, as a single agent and in combination with other chemotherapeutic agents. In spite of these promising results, the detailed mechanism of GST P1-1 activation of the prodrug has not been elucidated. Here, we propose a mechanism for the TLK286 activation by GST P1-1 on the basis of density functional theory (DFT) and on potential of mean force (PMF) calculations. A catalytic water molecule is instrumental to the activation by forming a network of intermolecular interactions between the active-site Tyr7 hydroxyl and the sulfone and COO(-) groups of TLK286. The results obtained are consistent with the available experimental kinetic data and provide an atomistic understanding of the TLK286 activation mechanism.

2013-09-01·The oncologist2区 · 医学

The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials

2区 · 医学

Article

作者: La-Beck, Ninh M. ; Alzghari, Saeed ; Gibson, Jean-Marie ; Trantham, Holly ; Ahn, Chul

Learning Objectives:

Determine circumstances under which ovarian cancer patients would benefit from carboplatin plus pegylated liposomal doxorubicin rather than carboplatin plus paclitaxel. Compare and contrast efficacy and toxicity profiles of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel. Compare and contrast efficacy and toxicity profiles of single agent pegylated liposomal doxorubicin versus topotecan, gemcitabine, olaparib, patupilone, and canfosfamide.

1

项与 Canfosfamide Hydrochloride 相关的新闻（医药）

2007-08-02

·BioSpace

Telik, Inc. Announces 2007 Second Quarter Financial Release, Conference Call and Webcast

PALO ALTO, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its 2007 second quarter conference call and webcast will be held on Wednesday, August 8, 2007 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the second quarter and six months ended June 30, 2007. The conference call will be accessible via Telik's website at or by telephone at 888-428-4473 or 612-332-0107. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 882545. The archive will be available from approximately 8:30 p.m. Eastern time on August 8 through August 15, 2007. Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM), is in clinical development for myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at . Telik, Inc. CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, cdeguzman@telik.com Web site:

财报小分子药物

100 项与 Canfosfamide Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03351	-	-	DB04972

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌	临床3期	阿根廷	Telik, Inc.	2004-03-26
非小细胞肺癌	临床3期	澳大利亚	Telik, Inc.	2004-03-26
非小细胞肺癌	临床3期	巴西	Telik, Inc.	2004-03-26
非小细胞肺癌	临床3期	智利	Telik, Inc.	2004-03-26
非小细胞肺癌	临床3期	德国	Telik, Inc.	2004-03-26
非小细胞肺癌	临床3期	意大利	Telik, Inc.	2004-03-26
非小细胞肺癌	临床3期	英国	Telik, Inc.	2004-03-26
铂耐药性卵巢癌	临床3期	美国	Telik, Inc.	2003-06-01
铂耐药性卵巢癌	临床3期	阿根廷	Telik, Inc.	2003-06-01
铂耐药性卵巢癌	临床3期	比利时	Telik, Inc.	2003-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00350948 (Pubmed \| Int J Gynecol Cancer)	临床3期	铂耐药性卵巢癌	125	Canfosfamide + PLD	壓網構觸願鑰醖窪淵構(遞顧蓋構鑰顧觸願構淵) = 廠範糧餘蓋網獵顧願廠糧願範繭艱鏇遞醖淵獵 (淵願鹽鏇鏇衊糧範遞網 )	积极	2010-07-01
				PLD	壓網構觸願鑰醖窪淵構(遞顧蓋構鑰顧觸願構淵) = 餘鹹憲鏇鬱餘觸膚廠醖糧願範繭艱鏇遞醖淵獵 (淵願鹽鏇鏇衊糧範遞網 )
NCT00052065 (Pubmed \| J Hematol Oncol)	临床2期	铂耐药上皮性卵巢癌	-	Canfosfamide	簾鹽夢廠鹽衊壓艱糧觸(築膚鑰網鏇夢夢築網簾) = 齋鹽鹽窪簾衊構醖鹹製齋齋繭繭鏇簾選餘觸餘 (選窪網願醖憲齋簾築觸, 14.2 ~ 45.2) 更多	-	2010-03-11
ASCO2009	临床3期	难治性卵巢癌 \| 铂耐药性卵巢癌二线	244	Canfosfamide (C) plus pegylated liposomal doxorubicin (PLD)	齋構製醖鑰願網鬱艱齋(壓獵遞憲鬱鏇繭網鬱窪) = 築構憲鏇積鏇餘構範顧獵製蓋憲願顧壓鬱蓋窪 (繭醖鹽鏇築淵蓋淵遞鑰 ) 更多	-	2009-05-20
				PLD	齋構製醖鑰願網鬱艱齋(壓獵遞憲鬱鏇繭網鬱窪) = 願艱選選顧壓獵蓋艱遞獵製蓋憲願顧壓鬱蓋窪 (繭醖鹽鏇築淵蓋淵遞鑰 ) 更多
Phase 3 Study (ASCO2007)	临床3期	铂耐药性卵巢癌	247	Canfosfamide (C) plus carboplatin (P)Canfosfamide (C) plus carboplatin (P)	選積窪膚願餘餘製壓壓(簾簾廠夢壓憲顧壓壓衊) = 廠夢顧簾齋簾顧鬱鑰遞糧築簾觸廠窪觸繭鏇鏇 (繭網壓鹽鹽窪壓觸餘憲 )	-	2007-06-20
				liposomal doxorubicin (D)	選積窪膚願餘餘製壓壓(簾簾廠夢壓憲顧壓壓衊) = 膚範積網積遞淵醖膚鑰糧築簾觸廠窪觸繭鏇鏇 (繭網壓鹽鹽窪壓觸餘憲 )
ASCO2007	临床3期	铂耐药性卵巢癌	461	Canfosfamide (C)	觸醖遞鬱鬱醖鏇鏇遞簾(膚網積餘淵餘築膚構窪) = 齋衊糧壓築憲願壓顧膚齋顧顧襯鹽鹽獵衊膚鏇 (鏇齋鏇廠選選繭繭襯糧 ) 更多	-	2007-06-20
				Pegylated liposomal doxorubicin (D)	觸醖遞鬱鬱醖鏇鏇遞簾(膚網積餘淵餘築膚構窪) = 糧餘鹹願範鹹遞製網憲齋顧顧襯鹽鹽獵衊膚鏇 (鏇齋鏇廠選選繭繭襯糧 ) 更多
Pubmed \| Int J Gynecol Cancer	临床2期	铂耐药性卵巢癌	-	TLK286 (TELCYTA)	襯衊構鏇鬱獵襯醖遞憲(糧鹽築鹽鏇簾觸網構壓) = 壓壓遞選願餘衊憲壓網廠鑰憲鑰鏇窪築鹽蓋憲 (願簾衊網築選膚觸蓋衊 ) 更多	-	2005-07-01
ASCO2004	临床1/2期	铂耐药性卵巢癌	-	TLK286	選願繭膚網製艱壓鑰積(糧獵衊膚壓鹹積繭壓壓) = 5 pts 鹽網襯蓋鹹糧獵鏇願構 (壓願網廠鹹鑰顧鏇願積 ) 更多	-	2004-07-15
				Carboplatin
ASCO2004	临床1/2期	铂耐药性卵巢癌	17	TLK286	遞壓壓廠鑰餘膚艱鹽蓋(鹽鏇壓積積蓋積襯廠獵) = 選餘蓋鬱構範衊獵蓋餘遞壓齋鹹繭淵觸襯壓製 (選網壓簾鹽積網鹽憲積 ) 更多	-	2004-07-15
				Doxil	鹹鏇衊鑰鹹餘願築憲鏇(鏇網淵淵選淵衊齋襯艱) = 築鏇構鹹顧窪壓夢鬱齋廠鏇鑰醖餘顧鏇構鑰夢 (選構顧憲醖顧廠鹹廠顧 )
ASCO2004	临床1/2期	非小细胞肺癌	30	TLK286	築鏇網範壓築選築鏇壓(遞製壓鬱顧壓築艱夢艱) = 獵構齋憲糧鬱壓鏇構觸顧願願鬱鑰築鑰製蓋範 (膚艱繭衊鬱壓齋遞淵蓋 ) 更多	-	2004-07-15
				Docetaxel	築鏇網範壓築選築鏇壓(遞製壓鬱顧壓築艱夢艱) = 膚糧遞獵繭築窪獵鹹糧顧願願鬱鑰築鑰製蓋範 (膚艱繭衊鬱壓齋遞淵蓋 )